Categories AlphaGraphs, Earnings, Other Industries

Retail pharmacy lifts CVS Health in the first quarter

CVS Health Corporation (CVS) reported an increase of 2.6% in revenues to around $45.7 billion for the first quarter of 2018 compared to the prior year period. Net income rose 4.7% to $998 million or $0.98 per share. Adjusted EPS came in at $1.48, beating market estimates. CVS shares rose over 2% in premarket trade following the earnings release.

The quarterly results benefited from higher prescription volumes within the retail pharmacy business and a lower income tax rate.

In the Pharmacy Services segment, revenues grew 3.2% to about $32.2 billion, primarily driven by growth in pharmacy network and specialty claim volume as well as brand inflation. Pharmacy network claims processed during the quarter increased 6%. In the Retail/LTC segment, revenues rose 5.6% to about $20.4 billion, driven primarily by an increase in the same-store prescription volume of 8.5%.

Same-store sales increased 5.8% while pharmacy same-store sales grew 7.3% during the quarter. Front store same-store sales improved 1.6% in the quarter. The increase in pharmacy same-store sales was mainly driven by the rise in the pharmacy same-store prescription volumes, partially offset by a negative impact of approximately 280 basis points due to recent generic introductions.

CVS Health Q1 2018 Earnings Infographic
CVS Health Q1 2018 Earnings Infographic

 

CVS expects GAAP diluted EPS between $5.11 and $5.32, and adjusted EPS between $6.87 and $7.08 for the full year of 2018. For the second quarter of 2018, the company expects GAAP diluted EPS of $1.21-$1.26 and adjusted EPS of $1.59-$1.64.

Shareholders of both companies approved the proposed acquisition of Aetna by CVS Health on March 13, 2018. The regulatory approval process is proceeding as per expectations. The transaction is expected to close during the second half of 2018. Aetna reported its earnings on Tuesday where its adjusted EPS of $3.19 beat analyst estimates.

During the first quarter, CVS launched the Rx Savings Finder initiative to tackle rising drug prices. This initiative has helped to improve transparency and reduce costs for customers.

Most Popular

Context Therapeutics: Another clinical-stage oncology research firm to go public soon

The US primary markets seem to be having a record-breaking start to the year, with over $171 billion raised in the first half of 2021 compared to $168 billion for

Biogen (BIIB) Stock: Does FDA nod for Aduhelm offer a buying opportunity?

The pharmaceutical industry has been witnessing hectic activity for some time, with most drug makers either channelizing their resources for vaccine development or engaging in COVID care programs. Biotechnology giant

IPO News: Monte Rosa Therapeutics will go public this week, here are a few things to know

Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top